Hearing Aids May Reduce Risk of Depression, Anxiety, Dementia in Older Adults

Older adults who use hearing aids may be less likely to develop depression, anxiety, and dementia for at least three years after a hearing loss diagnosis compared with those who do not begin using hearing aids, according to astudy published Wednesday in theJournal of the American Geriatrics Society. In addition, these individuals appear less likely to get injured in a fall.“By providing enhanced hearing input, HAs [hearing aids] may facilitate greater social engagement, lower levels of effort to recognize sounds and speech, lower levels of depression or anxiety symptoms, higher levels of physical balance, and greater feelings of independence and self-efficacy,” wr ote Elham Mahmoudi, Ph.D., and colleagues at the University of Michigan.Mahmoudi and colleagues examined insurance claims data from 114,862 adults aged 66 and older who received a hearing loss diagnosis between 2008 and 2013. All the adults included in the analysis remained on the same coverage —a Medicare managed care plan that includes partial coverage for hearing aids—for at least three years after receiving the diagnosis of hearing loss.The analysis showed that about 11% of women and 13% of men diagnosed with hearing loss began using hearing aids. Over the next three years, the adults who used hearing aids had an 18% reduced risk of being diagnosed with Alzheimer ’s/dementia, 11% reduced risk of being diagnosed with anxiety or depression, and a 13% reduced risk of having an injuriou...
Source: Psychiatr News - Category: Psychiatry Tags: Alzheimer's anxiety dementia depression fall injury geriatric psychiatry health insurance hearing aid hearing loss Medicare Source Type: research

Related Links:

Conclusions: There were significant differences with respect to clinical characteristics and comorbidity prevalence according to metformin use among Korean type 2 diabetes patients. Long-term follow-up of these patients is necessary to observe how this difference will affect clinical outcomes for these patients. PMID: 32774367 [PubMed]
Source: International Journal of Endocrinology - Category: Endocrinology Tags: Int J Endocrinol Source Type: research
Authors: Chen GF, Cheng YR, Ye L, Wang MW, Zhou MY, Zhang F, Chen J, Feng ZH Abstract OBJECTIVE: The World Health Organization reported a cluster of cases of pneumonia of unknown cause detected on December 31, 2019 in China. Unfortunately, a 34-year-old Italian nurse has committed suicide after testing positive for coronavirus. It was the second case of suicide by a nurse in an Italian hospital and occurred only a few days after the first suicide. These consecutive suicides have aroused concern, and it is necessary to investigate the psychological issues of the medical staff in Italy regarding the COVID-19. PMI...
Source: European Review for Medical and Pharmacological Sciences - Category: Drugs & Pharmacology Tags: Eur Rev Med Pharmacol Sci Source Type: research
Publication date: Available online 13 August 2020Source: World Journal of Acupuncture - MoxibustionAuthor(s): Yan-jun DU, Yi-ming TAO, Qing TIAN, Peng ZENG, Wen-hui WU, Jia-huan XIAO
Source: World Journal of Acupuncture Moxibustion - Category: Complementary Medicine Source Type: research
Authors: Zhang H, Cao Y, Pei H, Wang H, Ma L, Wang Z, Diao X, Yang Y, Liu N, Wei Y, Li H Abstract Shenmayizhi formula (SMYZF) has been shown to have an effect on vascular dementia (VaD) in previous studies. The aim of this study was to evaluate whether a combination of SMYZF with Ginkgo extract tablets improves mild-to-moderate VaD. In this 12-week, randomized, double-blind, controlled study, we randomly assigned 196 patients with VaD (aged 50-85 years) to either the SMYZF group (n = 98) or the Ginkgo group (n = 98). All patients received Ginkgo extract tablets as a basic treatment, whil...
Source: Evidence-based Complementary and Alternative Medicine - Category: Complementary Medicine Tags: Evid Based Complement Alternat Med Source Type: research
CONCLUSIONS: Use of HAs is associated with delayed diagnosis of AD, dementia, depression, anxiety, and injurious falls among older adults with HL. Although we have shown an association between use of HAs and reduced risk of physical and mental decline, randomized trials are needed to determine whether, and to what extent, the relationship is causal. The Study in Context: Hearing aids, by reducing cognitive load, can improve brain function in persons with hearing loss 46.7 million Americans have Alzheimer’s Disease brain pathology today, so it’s urgent to prevent or at least delay progression to clinical disea...
Source: SharpBrains - Category: Neuroscience Authors: Tags: Cognitive Neuroscience Health & Wellness Technology anxiety dementia depression fall-related injuries hearing aid hearing loss Medicare older-adults Source Type: blogs
OBJECTIVE: To examine the association between hearing aids (HAs) and time to diagnosis of Alzheimer disease (AD) or dementia, anxiety or depression, and injurious falls among adults, aged 66 years and older, within 3 years of hearing loss (HL) diagnosis. ...
Source: SafetyLit - Category: International Medicine & Public Health Tags: Age: Elder Adults Source Type: news
FRIDAY, Sept. 6, 2019 -- Use of hearing aids is associated with lower risks for being diagnosed with Alzheimer disease, dementia, depression, anxiety, and injurious falls among elderly adults diagnosed with hearing loss, according to a study...
Source: Drugs.com - Pharma News - Category: Pharmaceuticals Source Type: news
Conclusion: This novel technology discriminates and quantifies subtle differences in behavior and neurological impairments in subjects afflicted with neurological injury/disease. KINARM assessments can be incorporated into multi-center trials (e.g., monitoring stroke motor recovery: NCT02928393). Further studies will determine if KINARM Labs can demonstrate a clinical effect with fewer subjects over a shorter trial period. Disclosures/funding: Dr. Stephen Scott is the inventor of KINARM and CSO of BKIN Technologies.   Multiplexed mass spectrometry assay identifies neurodegeneration biomarkers in CSF Presenter: Chelsky...
Source: Innovations in Clinical Neuroscience - Category: Neuroscience Authors: Tags: Assessment Tools biomarkers Cognition Current Issue Drug Development General Genetics Medical Issues Neurology Patient Assessment Psychopharmacology Scales Special Issues Supplements Trial Methodology clinical trials CNS Su Source Type: research
Conclusion. A review of the literature suggests that there are adequate data supporting the efficacy and general safety of the low-dose use of trazodone for the treatment of insomnia. keywords: insomnia, hypnotics, treatment, trazodone, sedative Keywords: insomnia, hypnotics, treatment, trazodone, sedative Innov Clin Neurosci. 2017;14(9–10):24–34 Introduction Insomnia is characterized by difficulty falling asleep, difficulty staying asleep, or waking too early1 and is associated with significant impairments in daytime activities, which might occur despite adequate opportunities for sleep.2–6 Primary insom...
Source: Innovations in Clinical Neuroscience - Category: Neuroscience Authors: Tags: Current Issue Review hypnotics insomnia sedative trazodone treatment Source Type: research
By Brandon R. Peters, M.D. The news was enough to give you indigestion: Some of the over-the-counter and prescription medications most widely used to treat heartburn and acid reflux are linked to the development of dementia. The research suggesting a possible association is the latest in a string of implicated drugs over the past few years, including medications taken to treat anxiety, seizures, insomnia, and allergies. What is going on? Before emptying out the medicine cabinet, take a moment to consider the role of untreated obstructive sleep apnea. Scientific research can be difficulty to contextualize, especially when i...
Source: Healthy Living - The Huffington Post - Category: Consumer Health News Source Type: news
More News: Alzheimer's | Anxiety | Audiology | Dementia | Depression | Geriatrics | Health Insurance | HIV AIDS | Insurance | Managed Care | Medicare | Psychiatry | Women